Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203411 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Translational Oncology Research International.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00203411 is a Phase 2 study that has completed, run by Translational Oncology Research International. The registered enrollment target is 45 participants.
The verdict
NCT00203411, a Phase 2 study, has completed, sponsored by Translational Oncology Research International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of the bevacizumab and capecitabine combination in frail patients with untreated metastatic colorectal cancer.
Interventions
- DRUG Bevacizumab
- DRUG Capecitabine (Xeloda)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2006-03 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203411
The ClinicalTrials.gov registry entry for NCT00203411 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Translational Oncology Research International, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00203411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203411 about?
NCT00203411 is a clinical study titled "Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer". The purpose of this study is to evaluate the safety and effectiveness of the bevacizumab and capecitabine combination in frail patients with untreated metastatic colorectal cancer.
What is the current status of trial NCT00203411?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2006-03. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00203411?
The interventions under investigation include: Bevacizumab (DRUG), Capecitabine (Xeloda) (DRUG).
Who is sponsoring clinical trial NCT00203411?
This trial is sponsored by Translational Oncology Research International, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.